| 1 |
Development of Lead Compounds for Pancreatic Cancer Targeting GSPT1 and ZFP91 via a Molecular Glue Based Next-Generation Protein Degradation Strategy |
| TPD |
PDAC |
GSPT1, ZFP91 |
Hit |
CoBX Bio Inc. |
RS-2026-25502077 |
|
| 2 |
CK1α-Selective Molecular Glue Degrader for Solid Tumors |
| TPD |
Solid tumors |
CK1α |
Phase 1 |
Pin Therapeutics |
RS-2026-25501524 |
|
| 3 |
Clinical Development of the Oral BTK Degrader UBX-303061 for Relapsed/Refractory B-Cell Malignancies |
| TPD |
Relapsed/Refractory B-cell Malignancies |
BTK/HCK/LYN |
Phase 1 |
Ubix Therapeutics, Inc. |
RS-2025-25454729 |
|
| 4 |
Indentification of lead CDK6-KLHDC2 PROTAC molecules and technology transfer |
| TPD |
AML/ALL |
CDK6 |
Hit |
Yonsei University University-Industry Foundation |
RS-2025-25452139 |
|
| 5 |
Development of FLT3 Degrader Candidate Targeting Drug-resistant Mutants |
| TPD |
Acute myeloid leukemia (AML) |
FLT3 |
Candidate |
MagicBullet Therapeutics |
RS-2025-25450363 |
|
| 6 |
Discovery of Anti-Cancer Drug Candidates Using Molecular Glue-Based GSPT1 Degraders |
| TPD |
Multiple myeloma Lung cancer Prostate cancer |
GSPT1 |
Candidate |
Protier Biotech |
RS-2025-25444435 |
|
| 7 |
Development of the first-in-class anti-cancer leading compounds blocking growth factor receptors based on the mechanism of target-protein degradation |
| TPD |
solid tumors expressing mutant growth factor receptors (GFRs) |
MYO1D/GFRs |
Lead |
Vaxcell-Bio |
RS-2025-25444375 |
|
| 8 |
Development of TEAD Interface3 Targeting Protein Degrader |
| TPD |
NF2-mutated cancer |
TEAD |
Hit |
Korea Research Institute of Chemical Technology |
RS-2025-02223174 |
|
| 9 |
Development of Self-Assembling Peptide-Based PROTAC Nanodrug for Overcoming Drug Resistance to EGFR Inhibitors |
| TPD |
Colon cancer, Head & neck cancer, NSCLC |
EGFR |
Hit |
Ewha Womans University |
RS-2025-02223093 |
|
| 10 |
Identification of Molecular Glue drug Candidates for PLK1 Degradation |
| TPD |
TNBC |
PLK1 |
Candidate |
AevisBio, Inc |
RS-2025-02212974 |
|
| 11 |
Development of lead compounds as a SHP2 degrader for the treatment of KRAS mutant cancer |
| TPD |
KRAS (+) Pancreatic cancer/Solid cancer |
SHP2 |
Lead |
Elgen Therapeutic Inc. |
RS-2025-02202978 |
|
| 12 |
Development of mutant PI3Kalpha chaperone-mediated degrader candidate |
| TPD |
Breast cancer |
PI3Kα-chaperone |
Candidate |
MagicBullet Therapeutics |
RS-2024-00462810 |
|
| 13 |
Lead generation of intramolecular glue stabilizer targeting CBL-B as a treatment of colorectal cancer |
| TPD |
Colorectal Cancer (MSI-H/dMMR) |
CBL-B |
Lead |
IMMUSE Therapeutics |
RS-2024-00460474 |
|
| 14 |
Identification of estrogen receptor-degrading autophagytethering chimera (ATTEC) lead compounds for treating patients with ER-positive breast cancer |
| TPD |
Breast cancer (ER-positive) |
Estrogen Receptor |
Lead |
Korea Research Institute of Chemical Technology |
RS-2024-00459720 |
|
| 15 |
Development of CK1α selective molecular glue degrader for p53 wild-type solid cancer ONCOLOGY |
| TPD |
ACC, CRC |
CK1-alpha degrader |
Preclinical |
Pin Therapeutics Inc. |
RS-2024-00441932 |
|
| 16 |
Development of IKZF2 molecular glue degrader |
| TPD |
Solid tumor (NSCLC, Melanoma, TNBC) |
IKZF2 |
Lead |
Korea Reserch Institute Of Chemical Technology(KRICT) |
RS-2024-00332418 |
|
| 17 |
Discovery of AR-targeting ATTEC compounds for treating prostate cancer |
| TPD |
Castration-resistant prostate cancer |
Androgen receptor |
Lead |
Korea Reserch Institute Of Chemical Technology(KRICT) |
RS-2024-00332392 |
|
| 18 |
Discovery of VRK1 inhibitor for precision medicine of advanced/ refractory solid cancer |
| TPD |
Solid Tumor |
VRK1 |
Hit |
Korea Reserch Institute Of Chemical Technology(KRICT) |
RS-2023-00283832 |
|
| 19 |
Non.clinical development of CYRS1542, a GSPT1 Molecular Glue Degrader, for the treatment of patients with SCLC and AML |
| TPD |
SCLC, AML |
GSPT1 |
Preclinical |
Cyrus Therapeutics Inc. |
RS-2023-00282972 |
|
| 20 |
Preclinical development of a MET degrader as a novel NSCLC agent |
| TPD |
NSCLC |
MET (a receptor tyrosine kinase) |
Preclinical |
InnoCure Therapeutics |
RS-2023-00259138 |
|
| 21 |
Nonclinical development of AR degrader UBX.103335 for the treatment of metastatic castration.resistant prostate cancer |
| TPD |
Castration.resistant prostate cancer |
Androgen receptor (AR) |
Preclinical |
Ubix Therapeutics |
RS-2023-00258142 |
|
| 22 |
First-in-Class FLT3 Degrader Discovery Using PROTACs and Chemoproteomics |
| TPD |
Acute myeloid leukemia, AML |
FLT3 |
Lead |
Yonsei University Industry-University Cooperation Foundation |
RS-2023-00218195 |
|
| 23 |
Developing Lead compound of AURKA Degrader for a potential anti-cancer therapy |
| TPD |
Cancer |
AURKA |
Lead |
UPPthera, Inc. |
RS-2023-00217986 |
|
| 24 |
Pre-clinical development of anticancer candidate to treat small cell lungcancer (SCLC) through PROTAC-based PLK1 protein degradation |
| TPD |
NSCLC |
PLK1 |
Preclinical |
UPPPTHERA |
RS-2022-00167113 |
|
| 25 |
Development of therapeutics for acute myeloid leukemia with CK1alpha selective molecular degrader |
| TPD |
AML |
CK1α |
Candidate |
Pin Therapeutics |
RS-2022-00166852 |
|
| 26 |
An Oral, Selective, and Potent EGFR Mutant Protein Degrader for the Treatment of NSCLC |
| TPD |
NSCLC(EGFR mutation) |
EGFR |
Preclinical |
J2H Biotech |
HN22C0670 |
|
| 27 |
Polo-like kinase 1(PLK1) degradation using the N-degron pathway in PROTACs and its application of developing to non-small cell lung cancer(NSCLC) target drug candidates |
| TPD |
NSCLC |
PLK1 |
Candidate |
DANDI CURE |
HN22C0563 |
|
| 28 |
Identification of next-generation EGFR degraders to treat Non-Small Cell Lung Cancer (NSCLC) patients |
| TPD |
NSCLC |
EGFR mutation |
Lead |
Cyrus Therapeutics |
HN21C0965 |
|